Aprea Therapeutics, Inc announced that it has entered into a securities purchase agreement with new and existing healthcare focused institutional investors to issue 2,194,788 shares of its common stock at an issue price of $7.29 per share for gross proceeds of $16,000,000, Tranche A warrants to purchase up to 1,097,394 shares of common stock at an exercise price of $7.29 per share for an aggregate of up to $8,000,000 and Tranche B warrants to purchase up to 1,097,394 shares of common stock at an exercise price of $9.1125 per share for an aggregate of up to $10,000,000, resulting in aggregate gross proceeds of $34,000,000 on March 11, 2024. The transaction will include participation from Nantahala Capital, DAFNA Capital Management, Exome Asset Management and Stonepine Capital Management, among others, as well as certain Company insiders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.2 USD | -2.80% | -2.80% | +10.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.64% | 28.24M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- APRE Stock
- News Aprea Therapeutics, Inc.
- Aprea Therapeutics, Inc. announced that it expects to receive $16.000005 million in funding from Exome Asset Management LLC, Stonepine Capital Management LLC, Nantahala Capital Management, LLC, Dafna Capital Management, LLC and other company insiders